2026 ASCO GU Symposium - Testicular Cancer Awareness Foundation's Meet & Greet Social

On February 26, 2026, Testicular Cancer Awareness Foundation hosted a Meet & Greet Social at Marianne’s, the speakeasy-style venue tucked behind The Cavalier in San Francisco. Held during the 2026 ASCO Genitourinary Cancers Symposium, the event welcomed 55 attendees, including physicians, researchers, and leaders in the field of testicular cancer for an evening of conversation and connection. This marked the second year that Testicular Cancer Awareness Foundation has hosted the gathering at Marianne’s, a distinctive setting that continues to provide the perfect backdrop for bringing the community together.

The Meet & Greet Social was made possible through the generous support of Fennec Pharmaceuticals, whose ongoing partnership helps Testicular Cancer Awareness Foundation to create opportunities for medical experts to connect beyond the clinical setting. Events like this foster collaboration and the exchange of ideas that ultimately help advance the treatment and understanding of testicular cancer.

For Testicular Cancer Awareness Foundation, gatherings like this are also an opportunity to share the programs and resources we provide to patients and families navigate a diagnosis. These include financial assistance resources, educational materials, and survivorship support designed to help patients through treatment and beyond.

We were also pleased to share educational materials and “Survivor” wristbands with attending physicians to pass along to their patients. These small but meaningful items reflect our ongoing commitment to raise awareness and supporting individuals affected by testicular cancer.

Some guests also left with gifts from our Cause Marketing Partner, CaddySack, which has joined forces with Testicular Cancer Awareness Foundation to support early detection and education while bringing humor and heart to the golf course.

A special thank you to Fennec Pharmaceuticals for sponsoring this year’s Meet & Greet Social and for their continued support of our mission. Fennec developed PEDMARK, the first and only FDA-approved therapy to reduce the risk of cisplatin-induced hearing loss in adolescents and young adults (AYA) with cancer. PEDMARK is also recommended in the NCCN Clinical Practice Guidelines in Oncology for patients ages 15-39 receiving cisplatin chemotherapy.

The Testicular Cancer Awareness Foundation looks forward to continued engagement with the medical community at oncology and urology conferences and to new opportunities to bring the field together in support of patients affected by testicular cancer.